Farther Finance Advisors LLC Acquires 725 Shares of Cencora, Inc. (NYSE:COR)

Farther Finance Advisors LLC raised its position in shares of Cencora, Inc. (NYSE:COR) by 45.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,305 shares of the company’s stock after acquiring an additional 725 shares during the period. Farther Finance Advisors LLC’s holdings in Cencora were worth $518,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also bought and sold shares of COR. Swedbank AB increased its position in Cencora by 2.3% during the third quarter. Swedbank AB now owns 1,394,449 shares of the company’s stock valued at $313,863,000 after acquiring an additional 31,104 shares during the last quarter. United Bank increased its position in Cencora by 4.2% during the third quarter. United Bank now owns 5,601 shares of the company’s stock valued at $1,261,000 after acquiring an additional 225 shares during the last quarter. Oppenheimer & Co. Inc. increased its position in Cencora by 2.0% during the third quarter. Oppenheimer & Co. Inc. now owns 5,850 shares of the company’s stock valued at $1,317,000 after acquiring an additional 115 shares during the last quarter. CIBC Asset Management Inc increased its position in Cencora by 6.6% during the third quarter. CIBC Asset Management Inc now owns 39,237 shares of the company’s stock valued at $8,825,000 after acquiring an additional 2,438 shares during the last quarter. Finally, Empirical Finance LLC increased its position in Cencora by 2.1% during the third quarter. Empirical Finance LLC now owns 5,499 shares of the company’s stock valued at $1,238,000 after acquiring an additional 114 shares during the last quarter. Institutional investors own 97.52% of the company’s stock.

Insiders Place Their Bets

In other news, CAO Lazarus Krikorian sold 2,000 shares of the company’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $260.06, for a total transaction of $520,120.00. Following the transaction, the chief accounting officer now owns 20,154 shares in the company, valued at $5,241,249.24. This represents a 9.03 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Silvana Battaglia sold 1,678 shares of the company’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $228.72, for a total transaction of $383,792.16. Following the transaction, the executive vice president now owns 20,329 shares in the company, valued at approximately $4,649,648.88. This trade represents a 7.62 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 13,648 shares of company stock worth $3,382,462. 10.80% of the stock is owned by corporate insiders.

Cencora Stock Performance

Shares of Cencora stock opened at $258.09 on Monday. The company has a market capitalization of $50.05 billion, a PE ratio of 36.71, a P/E/G ratio of 1.31 and a beta of 0.51. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. The company has a 50-day simple moving average of $247.59 and a two-hundred day simple moving average of $239.15. Cencora, Inc. has a one year low of $214.77 and a one year high of $263.70.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, topping analysts’ consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. Research analysts expect that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were issued a $0.55 dividend. The ex-dividend date of this dividend was Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a yield of 0.85%. Cencora’s dividend payout ratio is presently 31.29%.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. JPMorgan Chase & Co. boosted their target price on shares of Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. Evercore ISI boosted their target price on shares of Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a research note on Thursday, February 6th. StockNews.com raised shares of Cencora from a “hold” rating to a “buy” rating in a research note on Wednesday, March 12th. Mizuho assumed coverage on shares of Cencora in a research note on Wednesday, December 4th. They set an “outperform” rating and a $280.00 target price for the company. Finally, Wells Fargo & Company boosted their target price on shares of Cencora from $251.00 to $274.00 and gave the company an “equal weight” rating in a research note on Friday. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, Cencora presently has a consensus rating of “Moderate Buy” and a consensus target price of $280.20.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.